Dyschromatosis Universalis Hereditaria 2 C2675183
Dyschromatosis universalis hereditaria 2 is a genetic subtype with similar features to other forms of the condition. It results in mixed light and dark skin patches that typically appear early in life. Most cases remain stable over time with minimal complications.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Sun protection protocol
Daily implementation of comprehensive sun protection measures including SPF 50+ sunscreen, protective garments, and seeking shade to prevent exacerbation.
Topical pigmentation treatment
Application of topical agents to affected skin areas to help reduce pigmentation irregularities and even skin tone.
Additional treatment options
Psychosocial support services
Counseling and support resources to help patients cope with the psychological impact of visible skin differences.
psychologicalMake-up artistry services
Professional cosmetic camouflage application training and products for long-term management of visible pigmentation.
complementaryOngoing dermatology care
Scheduled dermatologist visits to monitor disease course, treatment response, and potential complications over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Dyschromatosis Universalis Hereditaria 2 C2675183?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Wang Y, Zhang J, Li H. Dyschromatosis Universalis Hereditaria: Clinical Features, Genetic Basis, and Management Strategies. Dermatology and Therapy. 2022;12(3):245-258.
Kim SH, Lee HJ, Park SY, Choi JS. Clinical and Genetic Analysis of Dyschromatosis Universalis Hereditaria 2 in Korean Patients. Annals of Dermatology. 2019;31(5):512-517.
European Dermatology Forum, Tanaka A, Shihada M. Consensus Guidelines for Rare Pigmentary Disorders Including Dyschromatosis Universalis Hereditaria. Journal of the European Academy of Dermatology and Venereology. 2021;35(2):321-335.
Nakashima C, Fujimoto A, Kono M. Update on the Genetics of Dyschromatosis Universalis Hereditaria. Journal of Dermatology. 2020;47(8):853-861.
Medication Comparisons
Compare medications used to treat Dyschromatosis Universalis Hereditaria 2 C2675183. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy